Latest fund size
Undisclosed
Announced
June 14, 2026
Global HQ
United States
Members only
Check size
$1M-$5M
Members only
Stage focus
Seed, Series A, Series B
Members only
Regions of investment
North America, Europe, Israel
Members only
Star51 Capital is a New York-based Medtech venture investment platform founded by Adam Rosenwach and Tal Wenderow. The firm is structured as an ecosystem fund, combining strategic capital, operator networks, and a proprietary AI platform (StarVision™), to bridge the gap between Medtech innovation and acquisition. The fund invests at the convergence of Medtech and AI, with anchor support from Abbott and Mayo Clinic providing clinical validation, commercialization pathways, and domain expertise beyond capital.
star51capital.com
info@star51capital.com
Adam Rosenwach — Founding Managing Partner
Tal Wenderow — Founding Managing Partner
tal@star51capital.com
Members only
Names, roles, emails and LinkedIn profiles for the team, plus the fund's website.
Star51 invests in early and growth-stage Medtech and AI companies across interventional therapies, diagnostics, patient monitoring, personalization of healthcare delivery, and the digitalization of healthcare.
The fund sources opportunities from the US, Europe, and Israel, focusing on companies at critical inflection milestones from clinical validation through regulatory clearance and commercial scale.
Members only
What the fund looks for in founders and which sectors it backs.
Star51 Capital Fund I announced its first close in June 2026.
Fund size is not publicly disclosed.
The first close was led by Abbott and Mayo Clinic, with participation from senior Medtech executives, physicians, life science professionals, and significant commitment from the fund's general and operating partners, all of whom invested their own capital as LPs, directly aligning financial interests with portfolio outcomes.
Members only
Fund size, LPs and track record.
Leadership
Adam Rosenwach is Founding Managing Partner, with prior senior operating and finance roles at Medtech incubators and high-growth startups including Axon, Coridea, and Deerfield Catalyst. He holds a Wharton MBA and a degree from Berklee College of Music.
Tal Wenderow is Founding Managing Partner, founder of Corindus Vascular Robotics, which he led through its full lifecycle to a $1.1B acquisition by Siemens Healthineers; he subsequently served as a Venture Partner for a global Medtech strategic.
Raymond W. Cohen is Operating Partner, having engineered over $5B in exit value as CEO and Chairman of multiple Medtech companies.
Scott Pantel is Operating Partner, Founder and CEO of LSI, the leading Medtech investor conference platform, providing unparalleled access to the global Medtech ecosystem, deal flow, strategic acquirer relationships, and proprietary market intelligence.
Joe Mullings is Operating Partner, Chairman and CEO of The Mullings Group Companies, contributing the industry's leading Medtech executive search capabilities and Dragonfly, a Medtech marketing platform supporting portfolio companies' brand visibility and commercial momentum.
Investment Strategy
Star51 backs Medtech and AI companies from early through growth stage, leveraging its strategic anchor LPs (Abbott, Mayo Clinic) to provide clinical validation, commercialization pathways, and regulatory support that traditional funds cannot offer.
The firm's proprietary StarVision™ AI platform supports deal sourcing and portfolio evaluation. The ecosystem model integrates capital, operator expertise, executive search, marketing, and IP support, enabling portfolio companies to build toward acquisition readiness by top-tier strategics. The fund targets US, European, and Israeli deal flow.
Members only
Leadership, investment strategy, notable investments and exits.
